In correlation, significant increases in total caspase-3 levels were detected in both tumor types after rTBL-1 treatment (Figure 3D), with evident enrichments in the immunoblot of procaspase-3 (~31 kDa) and caspase-3 (17 kDa), suggesting increases in both expression and proteolytic activation of the effector caspase (MC-38, p = 0.004; CT-26, p = 0.042). The gene discussed is CASP3; the disease is neoplasm.